Regulus Therapeutics Director 1,750 Shares of Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc 1,750 shares of Regulus Therapeutics stock on the open market in a transaction dated Friday, July 11th. The was disclosed in a filing with the SEC, which is available at this link.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down 0.91% during mid-day trading on Friday, hitting $6.50. The stock had a trading volume of 40,353 shares. Regulus Therapeutics has a one year low of $5.40 and a one year high of $12.42. The stock’s 50-day moving average is $7.32 and its 200-day moving average is $8.10. The company’s market cap is $281.8 million.
Regulus Therapeutics (NASDAQ:RGLS) last released its earnings data on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.16. Analysts expect that Regulus Therapeutics will post $-0.84 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Regulus Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, June 17th. They now have a $7.80 price target on the stock. Finally, analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $14.76.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.